Resurfacing Marico's August 2025 Q1 FY26 results: revenue rises 23% to ₹3,259 crore; profit up 8%

Strong India and international performance lifted Marico's Q1 FY26 revenue and profit, per results reported in early August 2025. India revenue grew 27% year on year, while the company raised its fully diluted stake in Plix maker Satiya Nutraceuticals to 60%.

— FiledTue, 22 Sept, 2026, 08:19 IST·First seen Tue, 22 Sept, 2026, 08:18 IST·Source Financial Express · BrandWagon

What happened

Marico reported Q1 FY26 profit growth of 8.2% and revenue growth of 23%, led by a 27% rise in India sales. It increased its stake in Plix maker Satiya

Key facts

  • Q1 FY26 net profit Rs 513 crore, up 8.2% YoY from Rs 474 crore
  • Revenue from operations Rs 3,259 crore, up 23.31% YoY from Rs 2,643 crore
  • Total income Rs 3,315 crore, including Rs 56 crore other income
  • Total expenses Rs 2,659 crore versus Rs 2,075 crore
  • India revenue Rs 2,495 crore, up 27.17% from Rs 1,962 crore
  • International revenue Rs 764 crore, up 12.91% from Rs 681 crore
  • India PBT Rs 469 crore; international PBT Rs 213 crore
  • Marico raised its Satiya Nutraceuticals stake to 60% on a fully diluted basis

Why this matters

Marico’s increase to a 60% stake in Plix maker Satiya Nutraceuticals strengthens its control over a fast-growing nutrition platform and expands its premium wellness portfolio.

What to watch

  • India volume growth versus price-led revenue growth in the next two quarters.
  • Gross-margin movement and management commentary on copra, edible oil, packaging and currency costs.
  • Plix revenue growth, profitability, channel expansion and any increase in Marico’s stake beyond 60%.
  • International constant-currency growth, especially in Bangladesh, MENA, South Africa and Vietnam.
  • Advertising-and-promotion spend as a percentage of sales and its effect on operating-margin recovery.
  • Expand Plix distribution into modern trade, e-commerce and selected Marico general-trade outlets while retaining its digital-first positioning.
  • Increase marketing behind premium foods, healthy snacking, personal care and nutrition to convert revenue momentum into share gains.
  • Take calibrated price increases or reduce promotional intensity in inflation-affected core categories to protect gross margin.
  • Use the 60% Satiya Nutraceuticals stake to accelerate product launches, supply-chain integration and possible acquisition of the remaining minority stake over time.